If the wheels of justice turn at their current rate, most will die of old age before coming to trial.

ECONOMIST: Rwanda bleeds on

The good news for Dendreon is that the results of a 500-patient clinical trial that was presented in April are convincing even some die-hard skeptics.

FORBES: Provenge

Ina 237-person clinical trial, patients who used the NovoTTF-100A were as likely to die as those who got chemotherapy, but they were less likely to have side effects such as nausea, anemia, fatigue and serious infections.

FORBES: Cancer-Fighting Electric Hat Proves We Live In The Future